ArticleFrontiers in oncology2024
COVID-19 pandemic shifted epidemiology for cancer screening sites: breast, cervix, colon, and rectum.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Determinants of Early-Stage Breast Cancer Presentation in Western Kazakhstan: A Population-Based Analysis of Urban-Rural Disparities and Diagnostic Pathways (2015-2025).Medicina (Kaunas, Lithuania) · 2026Article
- Evaluation of a National Breast Cancer Screening Program in a Middle-Income Country: The Case of Kazakhstan.International journal of environmental research and public health · 2026Article
- Impact of the COVID-19 Pandemic on Hemato-Oncology Services: A Retrospective Dual-Center Cohort Study in Kazakhstan.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to assess the epidemiological changes in breast, cervical, colon, and rectal cancers in Kazakhstan before and during COVID-19, including early-onset cancer (EOC) diagnosed between the ages of 20 and 49, using data from the oncological service of the Republic of Kazakhstan for the 2017-2022 period. Methods: The cohort comprised patients aged 20 to 49 years (EOC) and 50 years and older [late-onset cancer (LOC)] from the total number of patients diagnosed each year during the study period of 2017 to 2022 for breast, cervical, colon, or rectal cancer. In order to indicate a difference in one-time intervals and characterize the global trend over the entire study period, annual percentage change (APC) and average APC (AAPC) were calculated, respectively. Results: Breast cancer detection rates increased by 22.8% for EOC and 15.9% for LOC from 2017 to 2022, and AAPC increased by 4.3% for EOC and 3.6% for LOC. During the COVID-19 restriction period, breast cancer detection rates decreased by 6.1% for EOC and 15.6% for LOC. Cervical cancer detection rates increased by 2.3% for EOC and 7.5% for LOC from 2017 to 2022, and AAPC increased by 0.9% for EOC and 1.6% for LOC. During the COVID-19 restriction period, cervical cancer detection rates decreased by 11.3% for EOC and 3.1% for LOC. Colon cancer detection rates increased by 18.4% for EOC and 14.3% for LOC from 2017 to 2022, and AAPC increased by 3.7% for EOC and 2.9% for LOC. During the COVID-19 restriction period, colon cancer detection rates decreased by 14.4% for EOC and 5.8% for LOC. Rectal cancer detection rates increased by 13.6% for EOC and 19.2% for LOC from 2017 to 2022, and AAPC increased by 3.0% for EOC and by 3.9% for LOC. During the COVID-19 restriction period, rectal cancer detection rates increased by 18.6% for EOC and decreased by 12.0% for LOC. Conclusion: The epidemiological indicators of population cancer screening worsened during the COVID pandemic; the detection rate decreased by 6.1% for breast EOC and 11.3% for cervical EOC, while there was an increase by 38.0% in EOC for colon cancer in men and by 8.0% in EOC for rectal cancer in men and 31.1% in women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.